Determination of lower cut‐off levels of adalimumab associated with biochemical remission in Crohn's disease

BACKGROUND AND AIM: Adalimumab is administered and dosed using a standardized treatment regimen. Although therapeutic drug monitoring (TDM) may help optimize treatment efficacy, the lower cut‐off concentration of adalimumab needed to retain disease remission has not been established. This cross‐sect...

Descripción completa

Detalles Bibliográficos
Autores principales: Carlsen, Arne, Omdal, Roald, Karlsen, Lars, Kvaløy, Jan Terje, Aabakken, Lars, Steinsbø, Øyvind, Bolstad, Nils, Warren, David, Lundin, Knut Erik Aslaksen, Grimstad, Tore
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Publishing Asia Pty Ltd 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7273736/
https://www.ncbi.nlm.nih.gov/pubmed/32514446
http://dx.doi.org/10.1002/jgh3.12266

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7273736/
https://www.ncbi.nlm.nih.gov/pubmed/32514446
http://dx.doi.org/10.1002/jgh3.12266

Ejemplares similares